News
The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback